# Semaglutide Effects, Side Effects & Safety: What People Report > Semaglutide effects in plain English: the appetite-quieting benefit people describe, the nausea and sulfur burps they complain about, and the cited safety cautions. ## The short version This page is the honest, plain-English account of what semaglutide actually does to people — the good and the ugly. Two layers live here, kept strictly apart. First, what the research-use community reports: things people say happened to them, which are not proof of anything. Second, the safety cautions that come from real clinical trials and drug-monitoring data, each one cited. The one-line summary of the community reports: appetite goes quiet and weight comes off, but the stomach pays a tax — nausea, foul burps, and unpredictable bowels are common, especially early. The cited cautions cover the stuff that matters most: a thyroid-tumor boxed warning, pancreatitis, gallbladder disease, an eye-related signal in people with diabetes, muscle loss, and weight regain after stopping. No doses appear on this page. None of it is medical advice. ## What people report **These are effects reported by the research-use community — anecdotal, not clinical evidence, and not verified by controlled trials.** They are collected here for context, not as findings. No doses are attached to any of them. **The benefits people describe most** - **A quieter relationship with food.** The single most common thing people say is that the constant background chatter about food goes silent, often within a week or two. They feel full faster, eat a fraction of their old portions, and stop circling the kitchen. Many call it the most life-changing part. (Frequently reported.) - **Cravings drop.** Sweet-tooth and sugar cravings fade or vanish, and fried, greasy, high-fat food stops appealing — sometimes turning slightly off-putting. Several people say they drift toward lighter meals on their own. (Frequently reported.) - **Weight comes off.** The overwhelming majority report losing weight, often steady and substantial over months, with the pace slowing after the early stretch. Most tie it to eating much less, not to exercising more. (Frequently reported.) - **Steadier blood sugar.** Among people using it for type 2 diabetes, a common theme is markedly better blood-sugar and A1C readings, sometimes back into normal ranges. (Commonly reported.) - **Less interest in alcohol.** A recurring side note: the urge to drink fades along with food cravings, and some people simply lose interest. (Occasionally reported.) **The downsides people complain about most** - **Nausea, sometimes vomiting.** The single most reported side effect, mentioned by roughly a third of reviewers, peaking in the first weeks and after each dose step-up, usually easing within a week or two. It flares after overeating or fatty food. (Frequently reported.) - **Sulfur or "egg" burps.** A distinctive complaint: foul-smelling burps people compare to rotten eggs or sulfur, often after a dose increase, sometimes lasting hours or weeks, frequently with bloating and a sense of food sitting too long. People call them embarrassing and say they show up more than the official lists suggest. (Commonly reported.) - **Bowel chaos.** Both constipation and diarrhea, sometimes alternating. Hard, infrequent stools on one end; loose stools worse right after a dose or after rich food on the other. (Commonly reported.) - **Acid reflux and heartburn.** Often arriving alongside the burping and bloating, tracking with dose increases. (Occasionally reported.) - **Early fatigue.** Tiredness and low energy, especially the day or two after an injection and during the first weeks, usually easing with time. (Commonly reported.) - **Food aversions and taste changes.** Active aversions to fatty, fried, or meaty food, a metallic taste, and a heightened, unpleasant sensitivity to smells that can itself trigger nausea — people liken it to morning sickness. A few suppress appetite so far they forget to eat. (Occasionally reported.) - **Hair shedding and a gaunter face.** A smaller group notes more hair shedding a few months in, plus a thinner, more hollow face — both widely chalked up to losing weight fast rather than the drug, and the shedding usually described as temporary. (Sometimes reported.) - **Headaches and dizziness.** Often in the first days of a new dose and frequently linked to not drinking or eating enough; many say hydration helps. (Occasionally reported.) - **Injection-site reactions.** Mild redness, itching, a small bump, or tenderness where people inject — generally minor and short-lived. (Sometimes reported.) ## Safety & cautions These cautions come from clinical trials, drug labels, and pharmacovigilance (the formal monitoring of side effects after a drug is on the market). Each is cited. Where a concern is theoretical or extrapolated rather than a proven clinical finding, it says so. **The stomach is the main event.** Nausea, vomiting, diarrhea, and constipation are the dominant adverse effects in the trials and the leading reason people stop. In the pooled STEP weight-management analysis these were mostly mild-to-moderate and transient, clustered around the dose-escalation period, and a dedicated safety review put nausea at roughly one-third of patients [5]. This is mechanism, not bad luck: slowing the stomach's emptying is part of how the drug works [4][5]. **Thyroid boxed warning (history of medullary thyroid carcinoma or MEN-2).** GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors, drawn from rodents given very high exposures [6][5]. A dedicated assessment of thyroid cancer risk concluded that human data do not establish a clear increase attributable to semaglutide — so the human signal is unconfirmed — yet a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is treated as a contraindication on the strength of the animal finding [6][5]. **Pancreatitis (class warning).** Acute pancreatitis is a recognized class warning, and treatment is conventionally stopped if it is suspected [5]. Pancreatic-cancer signals remain ones for which firm conclusions cannot yet be drawn because of low numbers, not confirmed associations [5]. The caution is precautionary, not a demonstrated risk increase. **Gallbladder disease.** A dedicated safety review found increased biliary disease (gallstones) versus placebo [5]. It is attributed largely to the rate and amount of weight loss rather than direct drug toxicity — but the increase is a real trial and monitoring finding, not just theory [5]. **Eyes, in people with diabetes correcting blood sugar fast.** In SUSTAIN-6, diabetic-retinopathy complications were significantly more frequent on semaglutide (HR 1.76; 95% CI 1.11-2.78), concentrated in people with pre-existing retinopathy whose blood sugar dropped rapidly [2][5]. The leading read is early worsening driven by the speed of correction, not direct retinal toxicity; monitoring is advised when glucose is corrected quickly [2][5]. **Muscle loss.** A STEP-program DXA body-composition substudy found the weight lost included both fat and a meaningful share of lean (muscle) mass [11]. Because fast, large weight loss can erode muscle, this raises a sarcopenia concern, especially in older adults, and has driven research into protein intake and resistance training. The lean-mass loss is observed; the downstream muscle-frailty risk is a reasoned extrapolation [11]. **Weight regain after stopping.** Stopping is followed by substantial regain. In the STEP 1 extension, people regained a mean of roughly 11.6 percentage points within a year and cardiometabolic gains reverted toward baseline; the STEP 4 withdrawal design showed the same after switching to placebo [19][14]. This frames it as a chronic, not curative, intervention. **Hair shedding.** A pharmacovigilance disproportionality analysis flagged an alopecia reporting signal with semaglutide and tirzepatide, and a separate dermatology study tied telogen effluvium (reversible diffuse shedding) to the size and speed of weight loss [15][16]. The signal fits weight-loss-driven shedding rather than direct drug toxicity. **Pregnancy.** Contraindicated per the label. Because the half-life is about a week — effectively cleared only about five weeks after the last dose — guidance advises stopping well before a planned pregnancy, commonly cited as roughly two months [17]. The washout math is documented; the contraindication itself is a regulatory statement. **The oral tablet is fussy.** Oral semaglutide is co-formulated with the absorption enhancer SNAC and has very low oral bioavailability (~0.4-1%), so it must be taken on an empty stomach with only a little water and kept apart from other food, drink, and medicine — getting that wrong can substantially cut the absorbed dose [12][17]. That is a formulation requirement, not a toxicity. **Drug interactions are mostly mild.** A systematic review found the delayed stomach emptying generally does not cause clinically significant interactions, but advised monitoring narrow-therapeutic-index oral drugs during dose escalation [18]. Overall interaction risk is characterized as low. None of the above is a dosing instruction, and none of it is medical advice — it is cited context. ## Then and now Semaglutide is the product of decades of incretin-peptide chemistry at one manufacturer, built on an earlier GLP-1 analogue and engineered for once-weekly dosing through DPP-4 resistance and albumin binding [12]. It first reached FDA approval for type 2 diabetes in 2017, with an oral once-daily form following in 2019-2020 and a chronic weight-management indication in 2021; the cardiovascular risk-reduction indication followed the SELECT readout, and a fatty-liver (MASH) indication arrived in 2025 [3][12]. During a federally declared shortage from roughly 2022 to early 2025, compounding pharmacies were permitted to produce semaglutide; that pathway was curtailed once the shortage was declared resolved in 2025 — a regulatory wrinkle covered on the [Semaglutide research](/research) page. --- A plain-spoken audit of the semaglutide trial record with the cardiovascular outcomes read first and the hype read last — an editorial digest, not a clinic, a prescriber, or a vendor.